Unni S, et al. – Researchers performed a retrospective cohort study in patients with type 2 diabetes (T2D) in an electronic medical record database to compare real–world, 6–month A1C and weight outcomes for exenatide QW (EQW) vs. dulaglutide and vs. albiglutide. At 6 months, they found that all agents significantly reduced A1C, with no significant differences between agents or by baseline A1C in insulin–naive subgroups.

Methods

• Researchers recruited 2,133 EQW, 201 dulaglutide, and 131 albiglutide patients.
• For this study, overall mean (SD) age was 60 (11) years and 54% were men; neither differed between comparison groups.

Results

• They observed that mean baseline A1C was similar for EQW [8.3 (1.7)%] and dulaglutide [8.5 (1.5)% (p=0.165)], but higher for albiglutide [8.7 (1.7)% (p
• It was showed that overall mean A1C change was -0.5 (1.5)% (p
• The obtained data indicates that mean weight change was -1.4 (4.7) kg for EQW and -1.6 (3.7) kg for albiglutide (p=0.579), but was greater for dulaglutide at -2.7 (5.7) kg (p=0.001).
• They found similar outcomes in subsets of insulin-naive patients with baseline A1C ≥7.0% or ≥9.0%.